Michael Seifert is a Nephrology physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1600 7th Ave S
Birmingham, AL 352331711
Telephone
205-638-9781Provider last certified this registry record 14 Oct 2020.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ANI Pharmaceuticals, Inc.Program year20242 payments
- Azurity Pharmaceuticals, Inc.Program year20241 payment
- Alnylam Pharmaceuticals Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
42.9%Proton pump inhibitor21.4%Omeprazole100%Part D<11 patientsCorticosteroid21.4%Prednisone100%Part D<11 patientsAnti-infectives
33.9%Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor33.9%Valganciclovir Hcl100%Part D<11 patientsAntiparasitic
23.2%Antimalarial23.2%Atovaquone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2015–2026 per NIH RePORTER. The latest:
- Early Life Stress-induced Reprogramming of Ambulatory Blood Pressure and Vascular Function in Adolescence
University of Alabama at Birmingham
FY2026$313,358P01HL158500 - Early Life Stress-induced Reprogramming of Ambulatory Blood Pressure and Vascular Function in Adolescence
University of Alabama at Birmingham
FY2025$287,514P01HL158500 - Early Life Stress-induced Reprogramming of Ambulatory Blood Pressure and Vascular Function in Adolescence
University of Alabama at Birmingham
FY2024$335,551P01HL158500
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Giuseppe Remuzzi
Mario Negri Institute for Pharmacological Research
Marcello Tonelli
University of Calgary
Johan Ärnlöv
Dalarna University
Juan Jesús Carrero
Danderyds sjukhus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”